ProCE Banner Activity

ROSEWOOD Primary Analysis: Phase II Trial of Zanubrutinib and Obinutuzumab vs Obinutuzumab Alone in R/R Follicular Lymphoma

Slideset Download
Conference Coverage
Results of the ROSEWOOD trial suggest a favorable risk–benefit ratio for zanubrutinib and obinutuzumab, as indicated by improved ORR, DoR, PFS, and OS compared with obinutuzumab alone and no unexpected safety signals.

Released: June 06, 2022

Expiration: June 05, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab